MO vs PM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MO and PM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MO and PM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Altria Group is one of the largest tobacco companies in the United States, best known for the Marlboro cigarette brand sold through its Philip Morris USA subsidiary. Altria's core business is selling combustible cigarettes in the US market, where Marlboro holds a dominant share. Despite long-term declines in cigarette smoking rates, Altria has historically sustained revenue and profit by raising prices faster than volumes fall, a pricing power rooted in brand loyalty and an addictive product. The company also owns smokeless and oral tobacco brands (Copenhagen, Skoal, and the on! nicotine pouch line), the NJOY e-vapor brand, and stakes in other businesses. Altria is structured as a high-cash-return company: it pays one of the largest dividend yields among large-cap US stocks and returns substantial cash to shareholders through dividends and buybacks. The central long-term challenge is the secular decline of cigarette smoking and the company's mixed track record in transitioning to reduced-risk products. Founded in its modern form after the Philip Morris International spin-off in 2008 and headquartered in Richmond, Virginia, Altria is a defensive, high-yield consumer-staples stock.

Full MO guide

Philip Morris International is one of the world's largest tobacco and nicotine companies, selling Marlboro and other cigarette brands across roughly 180 markets outside the United States. A 2008 spin-off from Altria split the Marlboro trademark by geography: Altria sells it in the US, while PMI owns it everywhere else. What sets PMI apart today is the scale of its pivot away from combustible cigarettes. Its smoke-free portfolio, led by IQOS heated tobacco, ZYN nicotine pouches (gained through the 2023 Swedish Match acquisition), and VEEV vapes, reached about 43% of net revenues in early 2026 and is available in more than 100 markets. In Q1 2026 IQOS shipment volume grew double digits and surpassed Marlboro to become the company's number one nicotine brand by volume in the markets where it competes.

Full PM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MO drivers: Pricing power and Marlboro dominance; High dividend and cash returns.
• PM drivers: IQOS heated tobacco leadership; ZYN and the US oral-nicotine pouch push.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the secular decline in US cigarette smoking, which steadily shrinks Altria's core volumes; at some point pricing may not fully offset falling volumes. For PM, regulation is the dominant risk: tobacco and nicotine face constant scrutiny, and the US FDA's stance on nicotine pouches, flavors, and youth use could restrict or slow ZYN and other products in PMI's most promising growth market.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MO if you believe its drivers more; PM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MO and PM guides.

MO. Altria trades at a low earnings multiple and a very high dividend yield, reflecting the market's view of declining cigarette volumes and heavy regulatory risk against durable pricing power and cash generation. The low multiple is the trade-off for an income stream most investors expect to grow slowly at best. ESG exclusions and secular concerns keep the valuation compressed.

PM. Figures are approximate and tied to the asOf date; verify live numbers before acting. PMI tends to trade at a premium to slower-growing tobacco peers like Altria because IQOS and ZYN give it a real growth angle, so the multiple reflects the transition story as much as current earnings. Analysts favor its faster EPS growth, but that view assumes smoke-free momentum continues and regulation stays manageable.

Headline figures (approximate, early 2026): MO shows revenue (ttm) ~$20 billion (net of excise taxes; ~$24 billion gross), operating margin ~55% (high, reflecting cigarette pricing power), net income (ttm) ~$8-11 billion (varies with one-time items), eps (adjusted) ~$5.20; PM shows revenue (ttm) ~$40 billion, growing high single digits; Q1 2026 net revenues rose about 9% year over year, smoke-free mix / drivers Smoke-free products ~43% of net revenues, led by IQOS heated tobacco and ZYN nicotine pouches; IQOS is now the top nicotine brand by volume in its markets, margins / profitability Strong, staple-like margins; adjusted EPS guided to low-double-digit growth in 2026, faster than most consumer-staples peers, dividend Yield well above the broad market (roughly high-3% range), raised every year since the 2008 spin-off; higher payout ratio than some peers.

MO and PM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MO and PM exposure against your real portfolio. It is not an investment adviser.